Comment on draft of atopic dermatitis treatments updated guidelines
Comment by Feb. 17!
Comment by Feb. 17 for your feedback to be reviewed by the guideline development workgroup.
The AAD is seeking member comments on draft clinical practice guidelines on the management of atopic dermatitis (AD) with recently FDA-approved therapies. These guidelines provide evidence-based recommendations regarding the efficacy, effectiveness, and adverse effects of AD treatment. The development of these guidelines followed a systematic approach and recommendations were formed by a guideline work group that included experts in AD management from multiple clinical settings, methodologists, and a patient representative.
The comment period is open to all AAD members and comments are being accepted through Feb. 17. Feedback received will be provided to the guideline development work group for review.
If you have questions, please email Lindsy Frazer-Green at lfrazer-green@aad.org.
Draft guideline and supplement
There are two PDFs available for review.
The first is the draft guideline itself.
The second is a supplement to the guideline.
